JP2004537506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537506A5 JP2004537506A5 JP2002569152A JP2002569152A JP2004537506A5 JP 2004537506 A5 JP2004537506 A5 JP 2004537506A5 JP 2002569152 A JP2002569152 A JP 2002569152A JP 2002569152 A JP2002569152 A JP 2002569152A JP 2004537506 A5 JP2004537506 A5 JP 2004537506A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- ester
- alkyl
- independently
- thioester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 103
- -1 sulfite ester Chemical class 0.000 claims 95
- 125000000547 substituted alkyl group Chemical group 0.000 claims 79
- 150000002148 esters Chemical class 0.000 claims 63
- 150000003568 thioethers Chemical class 0.000 claims 56
- 150000007970 thio esters Chemical class 0.000 claims 52
- 229920001542 oligosaccharide Polymers 0.000 claims 48
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 47
- 150000002482 oligosaccharides Chemical group 0.000 claims 47
- 229920000642 polymer Polymers 0.000 claims 47
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 45
- 125000004093 cyano group Chemical group *C#N 0.000 claims 44
- 150000002772 monosaccharides Chemical class 0.000 claims 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 150000001408 amides Chemical class 0.000 claims 41
- 150000001413 amino acids Chemical class 0.000 claims 41
- 125000002252 acyl group Chemical group 0.000 claims 39
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 125000003441 thioacyl group Chemical group 0.000 claims 39
- 125000001072 heteroaryl group Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 28
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 28
- 125000003107 substituted aryl group Chemical group 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 27
- 150000002367 halogens Chemical class 0.000 claims 27
- 108091034117 Oligonucleotide Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 239000002777 nucleoside Substances 0.000 claims 14
- 239000002773 nucleotide Chemical group 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 13
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 claims 13
- 150000003833 nucleoside derivatives Chemical group 0.000 claims 12
- 230000005855 radiation Effects 0.000 claims 12
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 11
- 125000006239 protecting group Chemical group 0.000 claims 10
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 10
- 150000003555 thioacetals Chemical class 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000003003 spiro group Chemical group 0.000 claims 8
- 230000003111 delayed effect Effects 0.000 claims 7
- 150000001241 acetals Chemical class 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000002170 ethers Chemical class 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000008134 glucuronides Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000001506 immunosuppresive effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 125000005907 alkyl ester group Chemical group 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 125000003835 nucleoside group Chemical class 0.000 claims 2
- 239000003182 parenteral nutrition solution Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- LJYCXQWXOMTYTO-BCBMDIKESA-N (8R,9S,10R,13S,14S)-13-[9H-fluoren-9-yl(methoxy)methyl]-10-methyl-2,3,4,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-7,17-dione Chemical compound C1=CC=CC=2C3=CC=CC=C3C(C1=2)C([C@@]12C(CC[C@H]1[C@@H]1C(C=C3CCCC[C@]3(C)[C@H]1CC2)=O)=O)OC LJYCXQWXOMTYTO-BCBMDIKESA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000004449 DNA Virus Infections Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 206010051589 Large intestine polyp Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000009341 RNA Virus Infections Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010073395 Small intestine polyp Diseases 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 208000024716 acute asthma Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000022131 polyp of large intestine Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 210000001032 spinal nerve Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27262401P | 2001-03-01 | 2001-03-01 | |
| US09/820,483 US20030060425A1 (en) | 1998-11-24 | 2001-03-29 | Immune modulation method using steroid compounds |
| US32301601P | 2001-09-10 | 2001-09-10 | |
| US32873801P | 2001-10-11 | 2001-10-11 | |
| US34005401P | 2001-11-01 | 2001-11-01 | |
| US33801501P | 2001-11-08 | 2001-11-08 | |
| US34352301P | 2001-12-20 | 2001-12-20 | |
| PCT/US2002/006708 WO2002069977A1 (en) | 2001-03-01 | 2002-03-01 | Use of certain steroids for treatment of blood cell deficiencies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537506A JP2004537506A (ja) | 2004-12-16 |
| JP2004537506A5 true JP2004537506A5 (cg-RX-API-DMAC7.html) | 2005-12-22 |
Family
ID=27569546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569152A Pending JP2004537506A (ja) | 2001-03-01 | 2002-03-01 | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1372664A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004537506A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2002244247B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2439687A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002069977A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893044B2 (en) * | 1995-02-24 | 2011-02-22 | Epigenesis Pharmaceutical, Inc. | Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrosterone |
| US9155741B2 (en) | 2000-08-01 | 2015-10-13 | The Trustees Of The University Of Pennsylvania | Methods of using a methylxanthine compound |
| WO2009158713A1 (en) * | 2008-06-27 | 2009-12-30 | The Trustees Of The University Of Pennsylvania | Methods of using a methylxanthine compound |
| MXPA03007337A (es) | 2001-02-15 | 2005-03-07 | King Pharmaceuticals Inc | Composicion farmaceutica y de hormona tiroidea estabilizada y metodo de preparacion de la misma. |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| FR2831441B1 (fr) * | 2001-10-25 | 2003-12-26 | Oreal | Utilisation cosmetique de derives de la dhea |
| CA2484963A1 (en) * | 2002-05-01 | 2003-11-13 | Arthur Schwartz | 7-hydroxy-16a-fluoro-5-androsten-17-ones and 7-hydroxy-16a-fluoro-5-androstan-17-ones and derivatives thereof |
| US8569275B2 (en) | 2002-08-28 | 2013-10-29 | Harbor Therapeutics, Inc. | Steroids having 7-oxgen and 17-heteroaryl substitution |
| EP2298315A1 (en) * | 2002-08-28 | 2011-03-23 | Harbor BioSciences, Inc. | Therapeutic treatment methods |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| EP1615944A4 (en) | 2003-04-01 | 2010-08-11 | Harbor Biosciences Inc | ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE |
| US7517581B2 (en) | 2003-09-26 | 2009-04-14 | Parker-Hannifin Corporation | Semipermeable hydrophilic membrane |
| PL1919290T3 (pl) | 2005-07-12 | 2014-06-30 | Ampio Pharmaceuticals Inc | Sposoby i produkty do leczenia chorób |
| CN103211821A (zh) * | 2006-04-22 | 2013-07-24 | 霍利斯—伊登医药公司 | 药物和用途 |
| US8354396B2 (en) | 2006-11-17 | 2013-01-15 | Harbor Therapeutics, Inc. | Drug identification and treatment method |
| US8486926B2 (en) | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
| US8217025B2 (en) | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
| AU2007327011A1 (en) * | 2006-11-30 | 2008-06-05 | Hunter-Fleming Limited | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| RU2402338C1 (ru) * | 2009-03-20 | 2010-10-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ получения активированных мононуклеарных лейкоцитов |
| ES2523821T3 (es) | 2009-06-22 | 2014-12-01 | Ampio Pharmaceuticals, Inc. | Procedimiento de tratamiento de enfermedades |
| EA201500752A1 (ru) | 2012-12-19 | 2016-05-31 | Ампио Фармасьютикалс, Инк. | Способ лечения заболеваний |
| JP6077880B2 (ja) * | 2013-02-18 | 2017-02-08 | 株式会社ファンケル | ＴＮＦ−α産生抑制剤 |
| CN108314698A (zh) * | 2017-01-17 | 2018-07-24 | 刘珂 | 原人参二醇磷酸酯钠及其制备和其单独或多药联合在治疗肾病综合症中的应用 |
| US20220233542A1 (en) * | 2019-06-05 | 2022-07-28 | University Of Georgia Research Foundation | Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN111024843B (zh) * | 2019-12-18 | 2022-06-21 | 大连医科大学附属第一医院 | 用于诊断帕金森病的联合标志物及检测试剂盒 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2170124A (en) | 1935-12-07 | 1939-08-22 | Schering Ag | Compounds of the androstane and pregnane series and methods of producing the same |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3984566A (en) | 1974-02-25 | 1976-10-05 | Scott Eugene J Van | Method of alleviating the symptoms of dandruff |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| GB1523965A (en) | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
| US4234599A (en) | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
| US4246261A (en) | 1979-08-09 | 1981-01-20 | Scott Eugene J Van | Additives enhancing topical corticosteroid action |
| WO1981002671A1 (en) | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
| US4652443A (en) | 1983-06-07 | 1987-03-24 | Japan Atomic Energy Research Institute | Slow-release composite and process for producing the same |
| US4602008A (en) * | 1984-12-14 | 1986-07-22 | Progenics, Inc. | Alkylated etiocholanolones and use as an anti-diabetic, anti-obesity and erythropoietic agent |
| DK173704B1 (da) | 1985-04-17 | 2001-07-09 | Hoffmann La Roche | Fremgangsmåde til katalytisk oxidation af allyliske grupper |
| JPS6261916A (ja) | 1985-09-12 | 1987-03-18 | Fujisawa Pharmaceut Co Ltd | 持続性製剤 |
| US5188840A (en) | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| US5795987A (en) | 1986-07-17 | 1998-08-18 | Board Of Governors Of Wayne State University | Alkene intermediates for preparing 1,2-dioxetane compounds |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5811118A (en) | 1987-05-22 | 1998-09-22 | The Liposome Company, Inc. | Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations |
| DE3801229A1 (de) | 1988-01-18 | 1989-07-27 | Krupp Polysius Ag | Mahlverfahren sowie mahlanlage |
| US5043165A (en) | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
| US5262407A (en) | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
| US5407684A (en) | 1988-12-30 | 1995-04-18 | Virginia Commonwealth University | Use of DHEA as a medicinal |
| US5461042A (en) | 1988-12-30 | 1995-10-24 | Loria; Roger M. | Regulation of the immune system |
| US5128450A (en) | 1989-06-30 | 1992-07-07 | Urdal David L | Nonglycosylated human interleukin-3 analog proteins |
| JP2642486B2 (ja) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
| AU652130B2 (en) | 1989-09-25 | 1994-08-18 | University Of Utah Research Foundation | Use of steroid hormones in compositions for inducing T cell lymphokine production |
| US5837269A (en) * | 1989-09-25 | 1998-11-17 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| US5919465A (en) | 1989-09-25 | 1999-07-06 | University Of Utah Research Foundation | Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) |
| US5882678A (en) | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
| US5820848A (en) | 1990-01-12 | 1998-10-13 | The Liposome Company, Inc. | Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent |
| US5292730A (en) | 1990-08-29 | 1994-03-08 | Humanetics Corporation | Modulation of immune system with Δ5-androstenes |
| US5641766A (en) | 1990-08-29 | 1997-06-24 | Humanetics Corporation | UP-regulation of immune system with Δ 5-Androstenes |
| US5585371A (en) * | 1990-08-29 | 1996-12-17 | Humanetics Corporation | Treatment of immune system with Δ5-androstenes |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US5162198A (en) | 1991-02-08 | 1992-11-10 | Virginia Commonwealth University | Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation |
| US5254343A (en) | 1991-03-19 | 1993-10-19 | Bristol-Myers Squibb Company | Reduction of cutaneous atrophy |
| US5271944A (en) | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
| US5206008A (en) | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
| EP0656067A4 (en) | 1991-08-22 | 1995-10-25 | Univ Leland Stanford Junior | SCREEN TEST PROCEDURE FOR IMMUNE SUPPRESSIVE AGENTS. |
| US5837840A (en) | 1993-09-20 | 1998-11-17 | Board Of Trustees Of Leland Stanford Jr. University | NF-AT polypeptides and polynucleotides |
| US5461768A (en) | 1992-04-10 | 1995-10-31 | Nippon Light Metal Co., Ltd. | Electrically heatable caulking system and method |
| US5686438A (en) | 1993-03-09 | 1997-11-11 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5532230A (en) | 1993-03-09 | 1996-07-02 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| FR2696934B1 (fr) | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5635496A (en) | 1993-03-09 | 1997-06-03 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5846963A (en) | 1995-06-07 | 1998-12-08 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5977095A (en) | 1993-03-09 | 1999-11-02 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and respiratory distress syndrome |
| US5811418A (en) | 1993-03-09 | 1998-09-22 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5753640A (en) | 1995-06-07 | 1998-05-19 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5840277A (en) | 1993-03-30 | 1998-11-24 | Charlotte Hospital Authority | Treatment of chronic pulmonary inflammation |
| DE4311835A1 (de) | 1993-04-07 | 1994-10-13 | Boehringer Ingelheim Int | Verfahren zur Inhibierung der Transkription von Genen |
| US6083735A (en) | 1993-06-24 | 2000-07-04 | The General Hospital Corporation | Programmed cell death genes and proteins |
| US5424077A (en) | 1993-07-13 | 1995-06-13 | Church & Dwight Co., Inc. | Co-micronized bicarbonate salt compositions |
| US5478566A (en) | 1993-09-29 | 1995-12-26 | Loria; Roger M. | Stimulation of cytokine production |
| US5750336A (en) | 1994-02-10 | 1998-05-12 | The Salk Institute For Biological Studies | Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| EP0676469A3 (en) | 1994-04-04 | 1998-03-25 | Tadamitsu Kishimoto | Transcription Factor APRF |
| US5714163A (en) | 1994-06-27 | 1998-02-03 | Nexstar Pharmaceuticals, Inc. | Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties |
| US5658744A (en) | 1994-07-22 | 1997-08-19 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of identifying patients having an altered immune status |
| US5792757A (en) | 1994-08-04 | 1998-08-11 | Pherin Pharmaceuticals | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
| US5665591A (en) | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
| US6051373A (en) | 1994-12-07 | 2000-04-18 | Scriptgen Pharmaceuticals, Inc. | Methods for screening for inhibitors of the transcription-enhancing activity of the X protein of hepatitis B virus |
| US5455049A (en) | 1995-01-04 | 1995-10-03 | Ascent Pharmaceuticals, Inc. | Terfenadine oral powder |
| FR2733912B1 (fr) | 1995-05-11 | 1997-07-18 | Conservatoire Nat Arts | Compositions pharmaceutiques contenant des derives de steroides impliques dans le declenchement de la reponse immunitaire |
| US5736381A (en) | 1995-05-19 | 1998-04-07 | Davis; Roger J. | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| BR9608592A (pt) | 1995-06-06 | 1999-06-29 | Cocensys Inc | Esteróides neuroativos da série do androstano e do pregnano |
| US5859000A (en) | 1995-06-07 | 1999-01-12 | University Of Utah Research Foundation | Method for reducing mast cell mediated allergic reactions |
| CA2208215A1 (en) * | 1995-10-12 | 1997-04-17 | Supergen, Inc. | Liposome formulations of 5.beta. steroids |
| ES2192221T3 (es) | 1995-10-30 | 2003-10-01 | Oleoyl Estrone Developments S | Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso. |
| IT1284853B1 (it) | 1996-06-18 | 1998-05-22 | Consiglio Nazionale Ricerche | Impiego del 2-ciclopenten-1-one come induttore di hsp70. |
| ES2188932T3 (es) | 1996-04-04 | 2003-07-01 | Cilag Ag | Formulacion topica de vitamina d a base de liposomas. |
| US5858711A (en) | 1996-11-25 | 1999-01-12 | President And Fellows Of Harvard College | NF-AT-interacting protein NIP45 and methods of use therefor |
| US5958671A (en) | 1996-04-23 | 1999-09-28 | Presidents And Fellows Of Harvard College | Methods and compositions for regulating T cell subsets by modulating transcription factor activity |
| EP0891425A2 (en) | 1996-04-23 | 1999-01-20 | President And Fellows Of Harvard College | Methods and compositions for regulating t cell subsets by modulating transcription factor activity |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| WO1998011877A1 (en) | 1996-09-18 | 1998-03-26 | Dragoco, Inc. | Liposome encapsulated active agent dry powder composition |
| US5891924A (en) | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
| US6074850A (en) | 1996-11-15 | 2000-06-13 | Canji, Inc. | Retinoblastoma fusion polypeptides |
| US5885977A (en) | 1997-01-15 | 1999-03-23 | Humanetics Corporation | Use of Δ5 androstenes in the treatment of HIV wasting syndrome |
| US5869709A (en) | 1997-05-07 | 1999-02-09 | Humanetics Corporation | Process for effecting allylic oxidation |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US6242253B1 (en) | 1997-10-09 | 2001-06-05 | Regents Of The University Of California | IkB kinase, subunits thereof, and methods of using same |
| US6372732B1 (en) | 1997-11-19 | 2002-04-16 | Humanetics Corporation | Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus |
| US6174901B1 (en) | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
| US6107034A (en) | 1998-03-09 | 2000-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | GATA-3 expression in human breast carcinoma |
| AU752581B2 (en) | 1998-05-26 | 2002-09-26 | Peter Louis Carlen | Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| US6248781B1 (en) | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
| WO2000024245A1 (en) | 1998-10-28 | 2000-05-04 | President And Fellows Of Harvard College | REGULATION OF TH2 CELL ACTIVITY BY MODULATION OF NFATp AND NFAT4 ACTIVITY |
| AP2001002285A0 (en) * | 1999-03-23 | 2001-12-31 | Hollis Eden Pharmaceuticals Inc | Immunomodulatory steroids, in particular the hemihydrate of. 16 alpha.-bromoepiandrosterone. |
| AU784111B2 (en) | 1999-06-02 | 2006-02-09 | President And Fellows Of Harvard College | T-bet compositions and methods of use thereof |
| ATE413179T1 (de) * | 1999-10-25 | 2008-11-15 | Hollis Eden Pharmaceuticals | Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6348489B1 (en) | 2000-04-11 | 2002-02-19 | Daiichi Pharmaceutical Co., Ltd. | Method of treating traumatic brain injury and other neuronal disorders |
-
2002
- 2002-03-01 CA CA002439687A patent/CA2439687A1/en not_active Abandoned
- 2002-03-01 WO PCT/US2002/006708 patent/WO2002069977A1/en not_active Ceased
- 2002-03-01 EP EP02709780A patent/EP1372664A1/en not_active Ceased
- 2002-03-01 AU AU2002244247A patent/AU2002244247B2/en not_active Ceased
- 2002-03-01 EP EP09172321A patent/EP2135611A1/en not_active Withdrawn
- 2002-03-01 JP JP2002569152A patent/JP2004537506A/ja active Pending
-
2008
- 2008-03-13 AU AU2008201188A patent/AU2008201188B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537506A5 (cg-RX-API-DMAC7.html) | ||
| ES2292604T5 (es) | Éster S-fluorometílico del ácido 6 ,9 -difluoro-17 -[(2-furanilcarbonil)oxi]-11 -hidroxi-16 -metil-3-oxo-androsta-1,4-dien-17 -carbotioico como agente antiinflamatorio | |
| JP4388600B2 (ja) | コルチコイド化合物の硝酸エステル類およびその薬学的使用 | |
| AU2016350690B2 (en) | Methods for the preparation of obeticholic acid and derivatives thereof | |
| SK14162001A3 (sk) | Deriváty 1,4-benzotiazepín-1,1-dioxidu substituované cukrovnými zvyškami, spôsob ich prípravy, liečivá, ktoré ich obsahujú, a ich použitie | |
| JP2018528230A (ja) | 胆汁酸誘導体の調製のための方法および中間体 | |
| PL121569B1 (en) | Process for preparing novel esters of 4-halogen-3-oxoandrosteno-4-carbo-17-beta-thiolic acidten-4-karbotiolovojj kisloty | |
| PT876392E (pt) | Derivados de lactona de derivados 17beta-carboxi carbotio e amida androstano | |
| JP2000516224A (ja) | 修飾オリゴサッカライド | |
| PT85551B (pt) | Processo para a preparacao de derivados da pirimidina com actividade antiviral e de composicoes farmaceuticas que os contem | |
| JP3279574B2 (ja) | トリテルペン誘導体および肝疾患治療剤 | |
| HU221584B (hu) | Új vastagbél- (colon) vagy csípőbél- (ileum) specifikus, cukortartalmú szteroidszármazékok, ezeket tartalmazó gyógyszerkészítmények és előállításuk | |
| PT88648B (pt) | Processo para a preparacao de novos esteres de acido androstano 17-carboxilico, e de composicao farmaceutica que os contem | |
| PT2070940E (pt) | Conjugados de macrólidos com actividade anti-inflamatória | |
| HRP941012A2 (en) | Steroidal glycosides | |
| SK135195A3 (en) | Crystaline spirostalnylglycosidal, its monohydrate pharmaceutical agent on its base and method of production of crystaline steroid glycoside | |
| RU2177951C2 (ru) | ПРОИЗВОДНЫЕ ПРЕГНАНА, НЕЗАМЕЩЕННЫЕ В 17α-ПОЛОЖЕНИИ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ПРОМЫШЛЕННЫЕ ПРОДУКТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
| AU2018241798B2 (en) | Lactulose glycoside compound and preparation method and use thereof | |
| JPH09510735A (ja) | スピロスタニルグリコシド性結晶 | |
| JPH09512823A (ja) | アデノシン誘導体 | |
| PT883628E (pt) | Derivados 17beta-(2-oxo-tetra-hidrofurano-4-il)-tio-androstano (derivados de grupo 17beta-(lactona do acido gama-butirico)-tio) para o tratamento de inflamacoes composicoes farmaceuticas e processo para a sua preparacao | |
| CA2037092C (en) | Bile acid unsaturated derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| EP4043447A1 (en) | Halogenated tetracyclic triterpene derivative, preparation and application thereof | |
| JP2729803B2 (ja) | マンノビオース誘導体 | |
| JPH09500907A (ja) | ステロイドグリコシド |